STAT3 and Miyoshi myopathy: Thymoquinone has the potential to inhibit IL-6 induced STAT3 activation in multiple myeloma (MM) cells (U266 and RPMI8226), followed by blocking JAK and SRC, resulting in the suppression of the downstream signaling pathway.